BridgeMD
New treatment option for Parkinson Disease
Official title tDCS on Parkinson's Disease Cognition
ClinicalTrials.gov ID: NCT03025334
What this study is testing
- What it's testing
- Parkinson's disease (PD) has been classically regarded as a "movement disorder", so earlier work has focused on treating motor symptoms only. As PD patients now have longer life expectancy, the relatively slowly progressing cognitive deficits (compared to their motor deficits) have become one of the major challenges.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Patients must meet diagnostic criteria for idiopathic Parkinson's disease, defined as the presence of two or more of the cardinal clinical features...
- Ability to provide written informed consent
- defined by the Diagnostic and Statistical Manual of Mental Disorders; DSM-5)
- Age \> 40
- fluent in English.
You likely can't join if
- Patients with dementia (defined as a Montreal Cognitive Assessment score \< 18)
- Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities, ataxia, sensory loss, or pyramidal signs.
- Abnormal MRI
- metal implants or a cardiac pacemaker
- Pregnant or breastfeeding women (female people of child bearing potential will be screened for pregnancy before MRI imaging).
- severe dyskinesia that may interfere with the quality of the scan (e.g., dyskinesia involving head movement).
See the full eligibility criteria
- Patients must meet diagnostic criteria for idiopathic Parkinson's disease, defined as the presence of two or more of the cardinal clinical features of PD in the absence of known causes of parkinsonism such as...
- Ability to provide written informed consent
- defined by the Diagnostic and Statistical Manual of Mental Disorders; DSM-5)
- Age \> 40
- fluent in English.
- Patients' cognitive statuses will be evaluated by the participating neuropsychiatrist or a trained psychiatry or neurology resident.
- Patients with dementia (defined as a Montreal Cognitive Assessment score \< 18)
- Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities, ataxia, sensory loss, or pyramidal signs.
- Abnormal MRI
- metal implants or a cardiac pacemaker
- Pregnant or breastfeeding women (female people of child bearing potential will be screened for pregnancy before MRI imaging).
- severe dyskinesia that may interfere with the quality of the scan (e.g., dyskinesia involving head movement).
- severe hypertension.
- cardiovascular disease.
- Patients with a history of seizure, stroke, moderate to severe head injury, high intracranial pressure, severe headaches, or presence of other neurologic disease that may be associated with an altered seizure threshold...
- secondary conditions that may significantly alter electrolyte balance or lower seizure threshold.
- Family history of epilepsy.
The study team makes the final eligibility decision.
Where it's taking place
- Winnipeg, Manitoba, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Winnipeg, Manitoba, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.